The goal of this study was to describe the variation in hospital-based diagnostic care activities for patients with symptomatology suspect for breast cancer in The Netherlands. Two cohorts were included: the ‘benign’ cohort (30,334 women suspected of, but without breast cancer) and the ‘malignant’ cohort (2236 breast cancer patients). Hospital-based financial data was combined with tumor data (malignant cohort) from The Netherlands Cancer Registry. Patterns within diagnostic pathways were analyzed. Factors influencing the number of visits and number of diagnostic care activities until diagnosis were identified in the malignant cohort with multivariable Cox and Poisson regression models. Compared to patients with benign diagnosis, patients w...
Background The onset of the COVID-19 pandemic forced the Dutch national screening program to a halt ...
Purpose: We aimed to compare (1) treatments and time intervals between treatments of breast cancer p...
OBJECTIVES: Cancer survival rates vary widely between European countries, with differences in timeli...
The goal of this study was to describe the variation in hospital-based diagnostic care activities fo...
The goal of this study was to describe the variation in hospital-based diagnostic care activities fo...
Purpose: Patients may transfer of hospital for clinical reasons but this may delay time to treatment...
Objectives A growing body of evidence suggests longer time between symptom onset and start of treatm...
BACKGROUND: Various breast cancer (BC) treatments, such as chemotherapy and targeted therapies, incr...
The aim of this study was to determine the incidence, management and diagnostic outcomes of breast c...
BACKGROUND: To describe variation in staging and primary treatment by hospital characteristics inclu...
As the number of cancer survivors increases in the Netherlands, there is a concomitant increase in p...
Background & aim Reducing the duration of the diagnostic cancer care pathway is intensively pursued....
Background The onset of the COVID-19 pandemic forced the Dutch national screening program to a halt ...
Introduction: Patients with screen detected breast cancer tend to have small, non-palpable tumours w...
textabstractIn the Netherlands, breast cancer is the most frequent (30%) of all cancers in women. In...
Background The onset of the COVID-19 pandemic forced the Dutch national screening program to a halt ...
Purpose: We aimed to compare (1) treatments and time intervals between treatments of breast cancer p...
OBJECTIVES: Cancer survival rates vary widely between European countries, with differences in timeli...
The goal of this study was to describe the variation in hospital-based diagnostic care activities fo...
The goal of this study was to describe the variation in hospital-based diagnostic care activities fo...
Purpose: Patients may transfer of hospital for clinical reasons but this may delay time to treatment...
Objectives A growing body of evidence suggests longer time between symptom onset and start of treatm...
BACKGROUND: Various breast cancer (BC) treatments, such as chemotherapy and targeted therapies, incr...
The aim of this study was to determine the incidence, management and diagnostic outcomes of breast c...
BACKGROUND: To describe variation in staging and primary treatment by hospital characteristics inclu...
As the number of cancer survivors increases in the Netherlands, there is a concomitant increase in p...
Background & aim Reducing the duration of the diagnostic cancer care pathway is intensively pursued....
Background The onset of the COVID-19 pandemic forced the Dutch national screening program to a halt ...
Introduction: Patients with screen detected breast cancer tend to have small, non-palpable tumours w...
textabstractIn the Netherlands, breast cancer is the most frequent (30%) of all cancers in women. In...
Background The onset of the COVID-19 pandemic forced the Dutch national screening program to a halt ...
Purpose: We aimed to compare (1) treatments and time intervals between treatments of breast cancer p...
OBJECTIVES: Cancer survival rates vary widely between European countries, with differences in timeli...